<DOC>
	<DOCNO>NCT00012337</DOCNO>
	<brief_summary>RATIONALE : Some tumor need growth factor produce body 's white blood cell keep grow . Drugs ZD 1839 may interfere growth factor cause tumor cell die . PURPOSE : Phase II trial study effectiveness ZD 1839 treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>ZD 1839 Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy ZD 1839 patient metastatic renal cell cancer . II . Determine time disease progression patient treat drug . III . Determine safety drug patient . OUTLINE : Patients receive oral ZD 1839 daily . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients follow least 1 month . PROJECTED ACCRUAL : A total 16-46 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic renal cell carcinoma Bidimensionally measurable disease Bone metastasis site must least 1 bidimensionally measurable tissue mass CT MRI ( e.g. , expansile lesion ) Radiologic evidence disease progression symptom related disease No brain metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky 70100 % Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL ALT/AST great 2.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN Other : No prior malignancy within past 5 year unless potentially curatively treat deem low risk recurrence Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy recover No 1 prior biologic regimen No concurrent biologic therapy Chemotherapy : At least 4 week since prior cytotoxic therapy recover No 1 prior cytotoxic regimen No concurrent cytotoxic therapy Endocrine therapy : At least 4 week since prior hormonal therapy recover No 1 prior hormonal regimen No concurrent hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : At least 4 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2002</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>